News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Boehringer Ingelheim Corporation Sex Pill, Flibanserin May Not Aid Women, FDA Staff Say
June 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Boehringer Ingelheim GmbH’s sexual desire drug flibanserin may not be effective or safe, according to U.S. regulators weighing whether to approve the first pill designed to boost women’s libidos.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Boehringer Ingelheim
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Tariffs
Trump Delays Pharma Tariffs Yet Again
October 2, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
October 1, 2025
·
2 min read
·
Dan Samorodnitsky
Complete response letters
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease
October 1, 2025
·
2 min read
·
Tristan Manalac
Government
US Government Shuts Down, FDA Closed for New Applications
October 1, 2025
·
4 min read
·
Annalee Armstrong